Mounjaro (Tirzepatide)

Mounjaro (active ingredient: tirzepatide) is an FDA-approved, once-weekly injectable medication developed by Eli Lilly for the management of type 2 diabetes in adults. It belongs to a new class of drugs known as dual GIP and GLP-1 receptor agonists, offering powerful control over blood sugar levels while also supporting substantial weight reduction in many patients.

What is Mounjaro?

Unlike other GLP-1 medications, Mounjaro is the first-in-class dual-acting treatment that mimics two natural hormones:

• GIP (Glucose-dependent Insulinotropic Polypeptide)

• GLP-1 (Glucagon-like Peptide-1)

Together, these hormones improve insulin sensitivity, reduce appetite, slow digestion, and help regulate blood glucose levels.

Key Features

• Active Ingredient: Tirzepatide

• Form: Prefilled subcutaneous injection pen

• Dosage Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens

• Frequency: Once weekly

• FDA-Approved: For type 2 diabetes management

• Manufacturer: Eli Lilly

Benefits of Mounjaro

• Helps lower blood sugar (A1C levels) in adults with type 2 diabetes

• Supports significant weight reduction when combined with diet & exercise

• Improves insulin sensitivity and reduces glucose release from the liver

• Once-weekly dosing for convenience

• May reduce the risk of obesity-related complications

How to Use Mounjaro

• Administered as a subcutaneous injection (abdomen, thigh, or upper arm)

• Initial dose: 2.5 mg once weekly for 4 weeks

• Gradual increase to 5 mg and higher doses as prescribed

• Always follow your doctor’s guidance for dose adjustments

• Should be combined with diet and exercise for best results

Possible Side Effects

Like other GLP-1-based treatments, Mounjaro may cause:

• Nausea

• Diarrhea

• Vomiting

• Abdominal discomfort

• Decreased appetite

Serious but rare risks: pancreatitis, gallbladder problems, allergic reactions, and possible thyroid tumors. Immediate medical attention should be sought for severe symptoms.

Storage Information

• Store pens in the refrigerator (36°F to 46°F / 2°C to 8°C)

• Once in use, pens may be kept at room temperature (up to 86°F / 30°C) for 21 days

• Do not freeze and protect from direct sunlight

Why Choose Mounjaro?

• Dual-action therapy (GIP + GLP-1) for more effective results

• Proven blood sugar control and weight loss benefits

• Convenient once-weekly injection

• Backed by clinical studies and manufactured by Eli Lilly, a trusted pharmaceutical leader

Important Safety Information

• Not for use in type 1 diabetes or diabetic ketoacidosis

• Not recommended for individuals with a family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome

• Should only be prescribed and monitored by a licensed healthcare provider

Legal Disclaimer

This content is for educational and informational purposes only. Mounjaro is a prescription-only medication. Always consult your healthcare provider before starting treatment.